BiotechTube
Home/Pipeline/ALLO-329

ALLO-329

Autoimmune Disease

Phase 1Active - RESOLUTION Trial Now Enrolling

Key Facts

Indication
Autoimmune Disease
Phase
Phase 1
Status
Active - RESOLUTION Trial Now Enrolling
Company
Allogene Therapeutics

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotech aiming to lead the next revolution in cell therapy with its AlloCAR T platform, designed to deliver scalable, on-demand treatments. The company has advanced a portfolio into Phase 2, with key catalysts in 2026, including the pivotal ALPHA3 trial in frontline large B-cell lymphoma. Its strategy leverages multiplex gene-editing and a proprietary lymphodepletion regimen to enable safe, effective, and commercially viable allogeneic therapies.

View full company profile

Therapeutic Areas

OncologyAutoimmune Diseases

Other Autoimmune Disease Drugs

DrugCompanyPhase
Fusion ImmunotherapeuticHCW BiologicsClinical Trial
Autoimmune Disease ProgramCarisma TherapeuticsDiscovery
Not Specified (Autoimmune Focus)Narwhal BioPre-clinical
Undisclosed Precision BiologicRhapsogenPre-clinical
First-in-class autoimmune disorder targetGenesis TherapeuticsPre-clinical
GIM-407GeorgiamunePreclinical
Autoimmunity ProgramAccipiter BiosciencesPreclinical
Undisclosed Autoimmune ProgramTianTi BiotherapeuticsPreclinical
Undisclosed Transcription FactorTalus BioscienceDiscovery
AppusBioVectisPre-clinical
Leap 1121Ability BiotherapeuticsPreclinical